Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Some of these new modalities include blocking HBV gene expression with RNA therapeutics, immune-activators, and molecules targeting the viral capsid, which results in inhibition of multiple steps ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Currently, we are focused on the hepatitis B virus capsid, the cytoplasmic dynein motor domain, and the role of carbohydrates and glycoconjugates in immunity and disease. "Assembly properties of ...

Positive Phase 1b interim data released for ABI-4334, a next-generation highly potent capsid assembly modulator candidate for chronic HBV (cHBV) infection ABI-4334 was well-tolerated, with an ...